Egetis Therapeutics Receives FDA Breakthrough Therapy Designation for Tiratricol in MCT8 Deficiency Treatment
Egetis Therapeutics AB has received Breakthrough Therapy Designation from the FDA for its treatment tiratricol, a potential breakthrough for patients with the rare condition MCT8 deficiency.
3 minutes to read